Trial Profile
A prospective observational study of osimertinib as predictive marker against patients with EGFR T790M-positive NSCLC.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 May 2017 New trial record